QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO.OB) Announces Favorable Research Showing Potential of Parthenogenesis 2 comments
    Jan 14, 2011 11:31 AM | about stocks: ISCO

    International Stem Cell Corp. is focused on therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. The company yesterday voiced its favor of a recent announcement by researchers at Nationwide Children’s Hospital that shows the potential of parthenogenetic stem cells to treat genetic diseases such as Huntington’s disease, beta thalassemia or tuberous sclerosis.

    In a scientific paper entitled, “Gene therapy by allele selection in a mouse model of beta-thalassemia,” researchers describe how they used a mouse model of an inherited blood disorder that shows parthenogenesis may have the ability to create “genetically clean” stem cells.

    “We at ISCO are particularly pleased to note this animal model research into the potential of parthenogenetic stem cells since ISCO has created method for creating immortal human parthenogenetic stem cell (hpSC) lines. We are constantly seeking ways to use such technology to treat human diseases, and this announcement is a positive indication showing the potential of parthenogenetic stem cells to treat certain types of autosomal dominant diseases such as particular forms of beta thalassemia or even Huntington’s disease,” Dr. Andrey Semechkin, CEO of ISCO stated in the press release. “We expect that the transition from animal models to human therapy using parthenogenetic cells will continue to evolve as ISCO continues to conduct its own therapeutic research and to collaborate with researchers across the world to discover new ways to use parthenogenesis and parthenogenetic stem cells to cure human disease. We have great hope that animal research such as that just reported will open new doors to human therapy and look forward to making our human parthenogentic lines available for such therapies.”

    The paper was published in the Journal of Clinical Investigation by a team of researchers from the Center for Molecular and Human Genetics (Nationwide Children’s Hospital, Columbus, OH), the University of Pennsylvania, the University of North Carolina and the University of Minnesota led by John McLaughlin Ph.D.

    “ISCO is actively conducting research on the creation and application of differentiated derivatives of hpSC for therapeutic use,” Dr Semechkin stated. “Specifically, ISCO has initiated a number of pre-clinical animal studies utilizing both hepatocytes and separately retina pigment epithelium cells, derived from hpSC. ISCO’s scientists were also the first to demonstrate the ability of hpSC to differentiate into neural cells and to develop approaches to obtain stable lines of parthenogenetic neural cells. These achievements open up the opportunity to assess the efficacy and safety of using parthenogenetic stem cells as a source to create neural cells for the treatment of diseases such as Parkinson’s, Alzheimer’s, and other neurodegenerative disorders. The work presented by Dr. McLaughlin once again confirms ISCO’s unique position in the field of stem cell based therapies.”

    For more information visit internationalstemcell.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • deeppocketsgolf
    , contributor
    Comments (111) | Send Message
    Detailed Quote for International Stem Cell Corp. (ISCO.OB)


    $ 1.33, 0.08, (+6.40%), Volume: 215K


    Market Cap 96.3M, on 72.456M Shares; Pricey @ +1.24_77, (94%) per Downside;


    Per Cash Change Value, Since 2001; Development Stage Since ‘01; Approx 6M;
    [Total Funding approx 36M][Proceeds from Common Stock approx 22M]


    8.222_56 Cents / Share;


    Desc, Breakdown, Price: , Metric. , Weight. , Primary Weight Adj Trading Metric ,Year, Weight Adj Price.


    20. Net Inc or Loss: , PT Net Inc or Loss: 0.08_222_56 , (0.16) , 34 , (5.33), Price1, 2.80


    21.OperBalanceSHeet: , PtCash Chg OperBS: 0.0822256 , (158) , 12 , (1,846), Price2, 0.96


    22. Investing Cash Activity: , PTCash Chg Inv: 0.0822256 , (2) , 21 , (40.83), Price3, 1.75


    23. Debt Financing: , PT Cash Chg Debt Finance: 0.0822256 , 0.17 , 28 , 4.75, Price4, 2.33


    24. Net: Other / NonCash /Oper Exp : , PT Other/ Non Cash / Oper Exp: 0.0822256 , 0.52 , (11) , (5.64) , LowPrice, (0.9)


    Sum Trading At: ,Primary Metric(s) per CF, (160) ,Weighted per Price Range / Change, 84.404_12_21 ,Primary Weight Adj Trade Metric, (1,893.3) , Desired Range(1.67) off adjusted level price of 1.75; (121M) Total Market Cap


    Hey Goldman Sachs Flunky; who really cares about your Garbage 2K in Sales Threshold???


    Net$$M Reported: (38.035)
    MinRetGrowth: 0.04
    MinRetInv: 0.04
    Weighted Cost of Capital: 0.3248; Non-Cash Adj’s as % of Funding;
    Estimated Local Continuing Value in $$M: (0.012424)
    Estimated Factor NOT LOCAL in $$M: (300)
    Estimated ContinuingValue:Avg Desired Funding Proceeds $$M / R&D Exp: 3.722M
    Est NOT LOCAL Price on LT Fwd Value : 0.19_26
    0.0514, Factor Forward.
    3.75, Price To.


    Do not own Shares; Follow the Company;


    Profile and Website:


    The Non Goldman Sachs Problem BBQ Retail Matriarch(s) Product:


    Guinness Brew “39”; Sold in Dublin in 2005; Discontinued in 2006; Same as Guinness Stout; Same ABV, But lighter Taste; and some Bar Mix with CHEEZ-ITS; hahaha!!!
    Same 124 Calories and (0.00) grams of fat;


    Obviously, there is probably not a good pint of Stout in Houston; TX!!!


    And how about that Wilson “You can’t walk off the island, and don’t call me Juan” Valdez; hahaha!!!


    Stagnant Old Money Phila Sports Owners: SPEND SOME STINKING MONEY!!!
    27 Feb 2011, 03:45 PM Reply Like
  • baltbear
    , contributor
    Comments (56) | Send Message
    as an actual play in the stem sector, isco.ob is the most attractive play right now. the other 2 "pure plays" , btx and actc are wildly overpriced in relation to any rational metric.
    neither btx nor actc can present any even vaguely plausible story that leads to $0.001 ebitda within 2 years.
    isco can, and is executing on it.
    fd: clients in isco.
    27 Feb 2011, 05:07 PM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.